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Pramanicin is a novel anti-fungal drug with a wide range
of potential application against human diseases. It has
been previously shown that pramanicin induces cell
death and increases calcium levels in vascular endothe-
lial cells. In the present study, we showed that pra-
manicin induced apoptosis in Jurkat T leukemia cells
in a dose- and time-dependent manner. Our data reveal
that pramanicin induced the release of cytochrome c and
caspase-9 and caspase-3 activation, as evidenced by de-
tection of active caspase fragments and fluorometric cas-
pase assays. Pramanicin also activated c-jun N-terminal
kinase (JNK), p38 and extracellular signal-regulated ki-
nases (ERK 1/2) with different time and dose kinetics.
Treatment of cells with specific MAP kinase and caspase
inhibitors further confirmed the mechanistic involve-
ment of these signalling cascades in pramanicin-induced
apoptosis. JNK and p38 pathways acted as pro-apoptotic
signalling pathways in pramanicin-induced apoptosis, in
which they regulated release of cytochrome c and cas-
pase activation. In contrast the ERK 1/2 pathway ex-
erted a protective effect through inhibition of cytochrome
c leakage from mitochondria and caspase activation,
which were only observed when lower concentrations of
pramanicin were used as apoptosis-inducing agent and
which were masked by the intense apoptosis induction by
higher concentrations of pramanicin. These results sug-
gest pramanicin as a potential apoptosis-inducing small
molecule, which acts through a well-defined JNK- and
p38-dependent apoptosis signalling pathway in Jurkat T
leukemia cells.
Keywords: caspases; Jurkat; mitogen-activated protein ki-
nases; pramanicin.
Introduction
Pramanicin is a recently discovered potent antifungal
agent with a polar head group and an aliphatic side chain
(Figure 1). The growth-inhibitory effect of pramanicin on
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fungal organisms is seen with minimal inhibitory concen-
trations of 20–100 µM.1 Pharmacological applications of
pramanicin on mammalian systems have not been studied
extensively. It has been previously shown that pramanicin
increases cytosolic calcium concentrations and induces cell
death in endothelial cells,2 but the effects of pramanicin
on cancer cell lines have not been investigated.
The principal aim of all anti-cancer therapies and cancer
prevention approaches is to eliminate all tumor cells from
the human body. Disequilibrium between cell prolifera-
tion and death has been proposed to be a fundamental step
in carcinogenesis. Additionally, induction of apoptosis
(programmed cell death) is an effective mechanism used
to eradicate transformed, deleterious cells; as well, many
chemotherapeutic or chemopreventive agents act through
triggering of apoptotic pathways in tumor cells. The cel-
lular apoptotic machinery is formed by protein signalling
networks, which are finely tuned by protein-protein inter-
actions and protein modifications. The intrinsic and ex-
trinsic apoptotic pathways have been defined previously3
and protein kinases as well as various cysteinyl-specific
aspartate proteases (caspases) have been proposed to me-
diate apoptosis induced by cytokines, chemotherapeutics
and cellular stress through a highly organized network at
different signalling levels.4–6 Briefly, cleavage of initiator
caspases (caspase 8 and caspase 9) and the effector caspases
(caspase-3/7) and typical cellular features of apoptosis (nu-
clear condensation and formation of apoptotic bodies) have
been observed following the release of cytochrome c from
mitochondria in response to death receptor stimulation or
a direct intracellular insult.
In mammals three distinct groups of mitogen-activated
protein kinases (MAPKs) have been identified. c-Jun
N-terminal kinases (JNK) and p38 MAPKs have been
shown to be activated by cellular stress, UV radiation,
growth factor withdrawal and pro-inflammatory cy-
tokines (mainly TNFα and IL-1).7,8 Upon activation
through a dual tyrosine/threonine phosphorylation mech-
anism by their corresponding upstream kinases, JNK and
p38 phosphorylate various transcription factors such as
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Figure 1. Structure of pramanicin.
c-jun, ATF-2 and p53 with different substrate speci-
ficities and control their transcriptional activity.9 Both
JNK and p38 kinases have been shown to be involved
in pro-apoptotic or anti-apoptotic signaling pathways in
many different studies.10,11 However, many stimuli have
been shown to activate these kinases without inducing
apoptosis.12−14 The third group of MAPKs, extracellular
signal regulated kinases (ERK 1/2, p42/p44 kinases) were
demonstrated to be mainly activated by growth factors
and other mitogenic stimuli.15,16 In general, intensive re-
search on MAPKs has suggested that JNKs and p38 are
mainly involved in apoptosis and growth arrest, but ERK
1/2 are involved in cellular transformation, differentia-
tion and proliferation. Indeed, the cell type, origin of the
stimuli, co-activation of other signalling cascades as well
as the initial magnitude, duration and further amplifica-
tion of the activated signal transduction pathway deter-
mine the pro-apoptotic or anti-apoptotic characteristic of
the cellular target response. Thus activation patterns and
pro-/anti-apoptotic properties of each MAPK should be
evaluated carefully in the light of above parameters.
Here we report on the apoptotic effect of pramanicin
on Jurkat T lymphoblastic leukemia cells in a dose- and
time-dependent manner, as shown by MTT assay and
DNA fragmentation. In order to gain insight into the
mechanisms of this apoptotic response we followed the
activation of MAPKs and caspases in response to pra-
manicin treatment. Our results have clearly demonstrated
the involvement of JNKs and p38 as well as caspase-9 and
caspase-3 activation with respect to pramanicin-induced
apoptosis in Jurkat T lymphoblastic leukemia cells. Mi-
tochondrial cytochrome c is released by pramanicin with
similar time-kinetics to caspase-9 activation. Pramanicin
also induces an early and transient ERK activation, which
contributes to a partial protective effect against apoptosis.
To our knowledge, this is the first study that reports pra-
manicin as a potential novel therapeutic approach against
cancer, which acts through an intelligibly JNK- and p38-
dependent mechanism.
Materials and methods
Reagents and antibodies
Caspase-3 inhibitor, Z-DEVD-FMK (benzyloxycarbonyl-
Asp-Glu-Val-Asp-fluoromethylketone), caspase-9 inhi-
bitor, Z-LEHD-FMK (benzyloxycarbonyl-Leu-Glu-
His-Asp-fluoromethylketone) and general caspase
inhibitor, Z-VAD-FMK (benzyloxycarbonyl-Val-Ala-
Asp-fluoromethylketone) were obtained from BD
Biosciences Pharmingen, (San Diego, CA, USA). RPMI
1640 Medium was purchased from Biological Industries,
Rehovot, Israel. JNK inhibitor SP600125 (anthra[1,9-
cd]pyrazol-6(2H)-one), p38 inhibitor SB203580 (4-(4-
fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-
1H-imidazole) and MEK1/ERK inhibitor PD98059
(2′-amino-3′-methoxyflavone) were from Calbiochem
(San Diego, CA, USA). JNK, phospho-JNK (Thr 183/Tyr
185), p38, phospho-p38, ERK 1/2, phospho-ERK 1/2
and cytochrome c antibodies were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Caspase-9,
caspase-3 and β-actin antibodies were from Cell Signaling
Technology Inc. (Beverly, MA, USA). CoxIV (cytochrome
c oxidase subunit IV) antibody was purchased from
Abcam (Cambridge, UK). Milk Diluent Concentrate Kit
was obtained from KPL (Maryland, USA). Phosphatase
Inhibitor Cocktail 1, Phosphatase Inhibitor Cocktail 2,
digitonin, fetal bovine serum and other chemicals were
purchased from Sigma (Darmstadt, Germany) otherwise
indicated.
Growth of Stagonospora and purification
of pramanicin
Stagonospora Sp. ATCC 74253 (American Type Culture
Collection, Rockville, MD, USA) was cultured in liq-
uid medium LCM, with the glucose content reduced to
40 g/L (100 mL in each of twelve 500 mL Erlenmeyer
flasks). After seven days, the cultures were centrifuged
and the supernatant extracted with methyl ethyl ketone.
After concentration, the organic extracts were purified by
column chromatography (SiO2, 10% MeOH/EtOAc). Fi-
nal purification was by MPLC on a Merck LOBAR RP-8
column in MeOH–H2O (70:30), giving approx. 75 mg
of pramanicin, as previously described.17
Cell cultures and treatments
Jurkat T lymphoblastic leukemia cells were a kind gift of
Dr. Jean-Franc¸ois Peyron, Faculte´ de Me´decine Pasteur,
Nice, France and have been previously described.18 The
cells were grown in RPMI-1640 supplemented with
10% fetal bovine serum and penicillin/streptomycin
(100 U/mL, respectively) in a humidified incubator at
37◦C and 5% CO2. Cells were seeded in 6-well cul-
ture plates (1× 106cells/well), 60 mm culture flasks
(1× 107 cells/well) or 96-well plates (104 cells/well) and
treated as indicated in the experimental protocols. Ethanol
(≤0.05%, v/v) was added to all control wells in each
experiment.
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Cell viability and DNA fragmentation assays
Cell viability was determined using an MTT assay kit
(Roche, Mannheim, Germany) as per the manufacturer’s
protocol. Briefly, Jurkat cells in 96-well plates were
treated as indicated and ten µl of MTT labeling reagent
was added to each well, and the plates were incubated for
4 hours. The cells were then incubated in 100 µl of the
solubilization solution for 12 hours, and the absorbance
was measured with a microtiter plate reader (Bio-Rad,
CA, USA) at a test wavelength of 595 nm and a reference
wavelength of 690 nm. Percent viability was calculated
as (OD of drug-treated sample/control OD) ×100.
DNA fragmentation was detected as described before
with minor modifications.19 Briefly Jurkat cells (1 ×
107 cells/well) were plated on 60 mm culture flasks. After
indicated treatments, cells were harvested, washed twice
with ice cold PBS and lysed in lysis buffer [10 mM Tris-
HCl (pH 8.0), 10 mM EDTA, and 0.2% Triton X-100]
on ice for 30 min. Cells were subsequently centrifuged
at 13000g at 4◦C for 10 min; supernatant was collected
and transferred to a new tube. Supernatant was incubated
with RNase A (200 µg/mL) at 37◦C for 1 h and then
incubated with Proteinase K (4 mg/mL) with 1.5% SDS
solution at 50◦C for 2 h. Soluble DNA was isolated by
phenol-chloroform-isoamylalcohol extraction and ethanol
precipitation. Vacuum dried DNA pellets were dissolved
in TE buffer and resolved on 2% agarose gel for 2 h. DNA
fragments were visualized by staining with ethidium
bromide.
Western blot analysis
Treated and control Jurkat cells were harvested, washed
with ice-cold phosphate-buffered saline and lysed on ice
in a solution containing 20 mM Tris-HCl (pH 7.5),
150 mM NaCl, Nonidet P-40 0.5%, (v/v), 1 mM EDTA,
0.5 mM PMSF, 1 mM DTT, protease inhibitor cocktail
(Complete from Roche, Mannheim, Germany) and phos-
phatase inhibitors (Phosphatase inhibitor cocktail 1 and
2, Sigma, Darmstadt, Germany). After cell lysis cell de-
bris was removed by centrifugation 10 min at 13000 g
and protein concentrations were determined with Brad-
ford protein assay. Proteins (40 µg) were separated on a
10–15% SDS-PAGE and blotted onto PVDF membranes.
The membranes were then blocked with 5% dried milk
in PBS-Tween20 and incubated with appropriate primary
and horseradish peroxidase (HRP)-conjugated secondary
antibodies (Amersham Pharmacia Biotech, Freiburg,
Germany) in antibody buffer containing 10% (v/v) Milk
Diluent/Blocking concentrate. After required washes
with PBS-Tween 20, proteins were finally analyzed us-
ing an enhanced chemiluminescence detection system
(ECL-Plus, Amersham Pharmacia Biotech, Freiburg,
Germany) and exposed to Hyperfilm-ECL (Amersham
Pharmacia Biotech, Freiburg, Germany).
Detection of cytochrome c release
Release of cytochrome c from mitochondria was detected
as described previously.20 Jurkat cells were seeded in
6-well plates (1× 106 cells/well) and after indicated treat-
ments, cells were harvested, washed once with phosphate-
buffered saline (PBS) and lysed for 30 s in 100 µl ice-
cold lysis buffer (250 mM sucrose, 1 mM EDTA, 0.05%
digitonin, 25 mM Tris, pH 6.8, 1 mM dithiothreitol
(DTT), 0.1 mM PMSF and protease inhibitor cocktail
(CompleteMini, Roche, Germany). Cell lysates were cen-
trifuged at 13000 g at 4◦C for 3 min and supernatants
(mitochondria-free cytosolic extracts) and the pellets (mi-
tochondrial fraction) were separately obtained. Cytoso-
lic and mitochondrial fractions were separated on a 15%
SDS-PAGE and then analyzed by Western blot using anti-
cytochrome c antibody and HRP-conjugated secondary
antibody. Proteins were finally developed using an ECL-
Plus enhanced chemiluminescence detection system and
exposed to Hyperfilm-ECL.
Caspase activation assays
The enzymatic activity of caspase-3 and caspase-9 was de-
termined by using a caspase activation assay kit (Sigma,
Darmstadt, Germany). Jurkat cells were treated as indi-
cated, washed twice with ice-cold PBS and then resus-
pended in lysis buffer (250 mM HEPES, pH 7.4, 25 mM
CHAPS, 25 mM DTT). After 15 min of incubation on
ice, samples were centrifuged for 10 min at 10000 g at
4◦C, supernatants were collected and protein concentra-
tions were determined by Bradford protein assay. Ten µg
of protein were assayed in 200 µl of reaction solution
containing Ac-DEVD-AMC for caspase-3-like DEVDase
activity and Ac-LEHD-AMC for caspase-9 activity. The
released fluorescent AMC was monitored at an excitation
of 360 nm and emission of 460 nm using a Spectramax
Gemini XS multiplate spectrofluorometer (Molecular De-
vices, Sunnyvale, CA, USA). Results were calculated from
a standard curve of AMC and specific caspase activities
were derived as mean relative fluorescence units (RFU)/mg
protein. Data shown are mean ± SEM of three indepen-
dent experiments performed in triplicate.
Statistical analysis
The results are expressed as mean ± SEM and the mean
values were compared using Students t-tail test. Values
of p < 0.05, p < 0.01 and p < 0.001 were considered
statistically significant.
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Results
Pramanicin induces apoptosis in Jurkat cells
In order to investigate the effect of pramanicin on Jurkat
cells, we first evaluated the modulation of cell viability
using the MTT assay. As demonstrated in Figure 2A,
treatment of Jurkat cells with pramanicin significantly
affects viability of cells in a dose- and time-dependent
manner. Treatment of Jurkat cells with 100 µM pra-
manicin for 24 h decreases cell viability compared with
untreated control (13.48± 5.11% vs. 97.765± 1.96%,
∗∗∗ p < 0.001). Endonuclease-mediated degradation of
chromatin giving rise to DNA laddering is one of the hall-
marks of apoptosis. To investigate the effect of pramanicin
on DNA laddering, cells were incubated with differing
Figure 2. Pramanicin induces apoptosis in Jurkat cells in a dose- and time-dependent manner. (A) Jurkat cells were treated with 0–
100 µM pramanicin for 0–24 h and after incubation, cell viability was assessed using MTT assay. Results are expressed as means± SEM
from three independent experiments performed in duplicate. ∗∗ p< 0.01; ∗∗∗ p< 0.001 compared with untreated sample. (B) Jurkat cells
were treated with 0–100 µM pramanicin for 24 h and DNA fragmentation, which indicates apoptosis was detected as described in
Materials and Methods. C, Jurkat cells were treated with 100 µM for 0–24 h and time-dependency of apoptotic response was evaluated
using DNA fragmentation assay as described in Materials and Methods.
doses of pramanicin for 24 h and 100 µM pramanicin for
0–24 h. Jurkat cells treated with 50 and 100 µM pra-
manicin contained low molecular weight DNA species
that migrated as a ladder (Figure 2B). As well 100 µM
pramanicin induces DNA laddering from 12 h after ad-
ministration (Figure 2C).
Pramanicin induces caspase activation and
cytochrome c release from mitochondria
To examine the involvement of cytochrome c release
in pramanicin-induced apoptosis, we evaluated the level
of cytochrome c in mitochondrial and cytosolic protein
fractions by Western blot analysis. Pramanicin treat-
ment at 100 µM concentration induces the release of
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cytochrome c from mitochondria and its appearance in
the cytosol at 2 h (Figure 3A).
Additionally, Jurkat cells were treated with increasing
concentrations of pramanicin and as shown in Figure 3A,
cytochrome c release from mitochondria is induced in a
dose-dependent manner. The release of cytochrome c from
mitochondria to cytosol results in its binding to Apaf-1
followed by apoptosome formation and caspase-9 acti-
vation. The activation status of caspase-9 was assessed in
whole cell lysates using immunoblot analysis. Pramanicin
(100 µM) induces the processing and appearance of an ac-
tive caspase-9 intermediate (35 kDa) at 2 h, which is fol-
lowed by more evident and intense active caspase-9 bands
(Figure 3B). Furthermore we followed the dose kinetics
of caspase-9 activation by 8 h of pramanicin treatment
and as shown in Figure 3B, pramanicin induced caspase-9
activation in a dose-dependent manner with a maximum
effect at 100 µM concentration. In parallel, we investi-
gated caspase-9 activation through its ability to cleave its
specific substrate (Ac-LEHD-AMC) and formation of the
fluorogenic AMC compound. The specificity of the assays
was confirmed by inhibitor studies and internal positive
controls. As shown in Figure 3B, pramanicin induces the
activation of caspase-9 at a dose and with time kinetics
similar to results demonstrated by immunoblot analysis,
with detection of maximum activation at 100 µM con-
centration and at 2 h post-treatment.
The death receptor and mitochondrial apoptosis inter-
sect at activation of effector caspases; therefore we analyzed
the time and dose kinetics of pramanicin-induced caspase-
3 activation in Jurkat cells. Processing of procaspase-
3 was evaluated by immunoblotting when cells were
treated with pramanicin (100 µM) for 0–8 h and 0–
100 µM pramanicin for 8 h. As shown in Figure 3C,
pramanicin induced a prominent activation of caspase-3
at 4 h with the appearance of cleaved intermediate prod-
ucts of procaspase-3. This effect was dose-dependent and
activation of caspase 3 was evident at 100 µM pramanicin
concentration. To further address caspase-3 activity, we
also assayed caspase 3-like activity through its ability to
cleave the fluorogenic substrate Ac-DEVD-AMC and the
release of AMC was monitored as in caspase-9 assays. Pra-
manicin induces the activation of caspase-3 as shown in
Figure 3C, with prominent activation at 100 µM concen-
tration and at 4–8 h post-treatment. The results confirmed
the sequential activation of caspase-9 and caspase-3, which
indicates an intrinsic mitochondria-mediated signalling
pathway in pramanicin-induced apoptosis.
Pramanicin activates JNK, p38 and ERK 1/2
MAP kinases with different kinetics
Many studies have reported the role of MAPKs in apop-
tosis signalling and potential functional interactions be-
tween MAPK and caspase pathways determine the fate
of a cell in response to various stimuli. Therefore, we
next evaluated pramanicin-induced activation of MAPKs
using immunoblot analysis. Pramanicin at 100 µM con-
centration induced an immediate JNK activation starting
from 30 min post-treatment and maximum levels of JNK
phosphorylation were observed at 4 and 8 h (Figure 4A,
upper panel), without any significant change in JNK
protein levels. In addition, we performed concentration-
dependent experiments to identify the dose-dependency
of JNK activation by pramanicin and treatment of Jurkat
cells with pramanicin at different concentrations ranging
up to 100 µM for 4 h (Figure 4B, upper panel). As de-
tected by immunoblot analysis of phospho-JNK (p-JNK)
proteins, pramanicin induced a dose-dependent activa-
tion of the JNK pathway. p38 phosphorylation was also
induced at 30 min duration following pramanicin treat-
ment, returning to nearly basal levels at 8 h (Figure 4A,
middle panel). Elevation of p38 activation was also
dose-dependent with a maximum activation at 100 µM
pramanicin concentration (Figure 4B, middle panel).
Pramanicin treatment also induced an early, strong but
transient phosphorylation of both ERK1 and ERK2 MAP
kinases. Interestingly, ERK1 phosphorylation could not
be detected after 2 h but we were able to observe phos-
phorylated ERK2 even at 8 h after pramanicin treatment
(Figure 4A, lower panel). To evaluate the dose-dependent
activation of the ERK 1/2 pathway by pramanicin, we also
followed the phosphorylated and active ERK 1/2 proteins
by means of immunoblot analysis. As shown in (Figure 4B,
lower panel), pramanicin treatment induced activation of
both the ERK1 and ERK2 in a dose-dependent man-
ner with respect to untreated control cells, but the maxi-
mum activation of the ERK 1/2 pathway was detected at
50 µM pramanicin concentration. These findings demon-
strate that pramanicin is able to induce the activation of
all three MAPKs with different time kinetics and char-
acteristics. Thus, it was of interest to further evaluate the
crosstalk between caspase and MAP kinase activation cas-
cades as well as the specific involvement of each pathway
in pramanicin-induced apoptosis.
MAP kinases and caspases are functionally
involved in pramanicin-induced apoptosis
Activation of MAP kinases either upstream or down-
stream of mitochondria-mediated caspases activation has
been demonstrated to regulate apoptosis in various ex-
perimental models. Therefore, we investigated whether
activated MAP kinases and caspases are involved in
pramanicin-involved apoptosis. To evaluate the involve-
ment of JNK, p38 and ERK 1/2, Jurkat cells were treated
with pramanicin for 24 h in the absence and presence of
specific MAP kinase inhibitors and the apoptotic response
was evaluated by MTT and DNA fragmentation assays.
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Figure 3. Pramanicin induces mitochondrial cytochrome c release and caspase activation in Jurkat cells. (A) Jurkat cells were treated
with 100 µM pramanicin for 0–8 h (upper panels) or treated with 0, 20, 50 and 100 µM pramanicin for 8 h (lower panels). Following
indicated incubations, mitochondrial and cytoplasmic fractions of cytochrome c were detected by immunoblot analysis. CoxIV and β-
actin were probed as a loading control for mitochondrial and cytoplasmic fractions respectively. Results are representative of three
independent experiments. (B) Jurkat cells were treated with 0–100 µM pramanicin for 8 h (upper panels) or 100 µM pramanicin for
0–8 h (lower panels) and the activation of caspase-9 was evaluated by immunoblot analysis (performed by using a specific antibody
against active caspase-9) and fluorometric caspase assays. In caspase assays, results were expressed as mean± SEM from three
independent experiments performed in triplicate. (C) to examine the activation of caspase-3, Jurkat cells were treated with 0–100 µM
pramanicin for 8 h (upper panels) or 100 µM pramanicin for 0–8 h (lower panels) and the activation of caspase-3 was evaluated by
immunoblot analysis (performed by using a specific antibody against procaspase-3 and active caspase-3 fragments) and fluorometric
caspase assays. β-actin was probed as a loading control for immunoblots. In caspase assays, results were expressed as mean± SEM
from three independent experiments performed in triplicate.
Figure 4. Pramanicin activates MAP kinases with different time- and dose-kinetics. A, Jurkat cells were treated with 100 µM pramanicin
for 0–8 h and total proteins were isolated. Activities of JNKs, p38 and ERK 1/2 MAP kinases were detected by immunoblot analysis.
Specific antibodies against total and phospho-JNKs (upper panel), total and phospho-p38 (middle panels) and total and phospho-ERK
1/2 (lower panels) were used for immunoblot analyses. B, for dose-dependent MAP kinase activation Jurkat cells were treated with 0–
100 µM pramanicin for 4 h to detect JNK activation (upper panels), 2 h for p38 activation (middle panels) and 30 min for ERK 1/2 (lower
panels) activation. Total proteins were isolated and analyzed by means of immunoblot. Specific antibodies were used to detect total and
phospho-MAP kinases as described above. β-actin was probed as a loading control for immunoblots and results are represententative
of three independent experiments.
As shown in Figures 5A and B, Lanes 7, JNK in-
hibitor (SP600125) at 10 µM concentration significantly
protects Jurkat cells against pramanicin-induced apop-
tosis (∗∗∗ p < 0.001, compared to pramanicin (100 µM)
treated cells). p38 inhibitor (SB203580) at 10 µM con-
centration also abrogated pramanicin-induced apoptosis
(∗∗∗ p < 0.001, compared to pramanicin (100µM) treated
cells) (Figures 5A and B, Lanes 6).
ERK inhibitor (PD98059) does not have any signifi-
cant effect on pramanicin-induced apoptosis at 100 µM
concentration (Figures 5A and B, Lanes 3), but interest-
ingly PD98059 enhances pramanicin-induced apoptosis
of Jurkat cells at 50 µM concentration (§ p < 0.05, com-
pared to pramanicin (50 µM) treated cells) (Figures 5A
and B, Lanes 4 and 5 respectively). These results suggest
that activation of JNK and p38 pathways are necessary
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Figure 5. Effects of MAP kinase and caspase inhibitors on pramanicin-induced apoptosis in Jurkat cells. Jurkat cells were pretreated
with specific MAP kinase and caspase inhibitors (10 µM ERK inhibitor (PD98059), 10 µM p38 inhibitor (SB203580) and 10 µM JNK
inhibitor (SP600125) for 1 h; 20 µM pancaspase inhibitor (z-VAD-FMK), 20 µM Caspase-9 inhibitor (z-LEHD-FMK) and 20 µM Caspase-
3 inhibitor (z-DEVD-FMK) for 30 min) which is followed by 100 or 50 µM pramanicin treatment for 24 h. Untreated negative controls
and cells treated with 100 or 50 µM pramanicin without inhibitor pre-treatment were also involved in experimental panels. The lanes
for specific treatments are indicated in the figure. After incubation, the effects of specific kinase and caspase inhibitors on pramanicin-
induced apoptosis were evaluated by A, DNA fragmentation and B, MTT cell viability assay as described in Materials and Methods. MTT
results are expressed as means± SEM from three independent experiments performed in duplicate. ∗ p< 0.01; ∗∗ p< 0.001 compared
with 100 µM pramanicin- treated sample. § p< 0.05, compared with 50 µM pramanicin-treated sample.
for pramanicin-induced apoptotic response, but ERK 1/2
has a potential pro-survival role.
To determine the functional involvement of caspases
in pramanicin-induced apoptosis, we incubated Jurkat
cells with pancaspase inhibitor (z-VAD-FMK), caspase-
9 inhibitor (z-LEHD-FMK) and caspase-3 inhibitor (z-
DEVD-FMK) in the absence or presence of pramanicin
(100 µM) and then the apoptotic response was assessed
using MTT and DNA fragmentation assays. As shown
in Figures 5A and B, Lanes 8 pancaspase inhibitor pre-
vents pramanicin-induced apoptosis. As well, caspase-9
inhibitor (Figures 5A and B, Lanes 9) and caspase-3
inhibitor (Figures 5A and B, Lanes 10) show a protec-
tive effect against pramanicin-induced apoptosis. These
results confirm that pramanicin triggers a pro-apoptotic
pathway in Jurkat cells, which involves MAP kinases and
caspases.
JNK and p38 pathways regulate cytochrome
c release and caspase activation in
pramanicin-treated Jurkat cells
In order to clarify the functional mechanisms by which
MAP kinases and caspases regulate pramanicin-induced
apoptosis, we tried to identify the mechanistic relation-
ship between two pathways. As a starting point, we
pretreated Jurkat cells with JNK inhibitor (SP600125)
for 1 h before pramanicin (100 µM) treatment for 8 h
and followed cytochrome c release from mitochondria
and caspase-9 and caspase-3 activation by means of im-
munoblot analysis and caspase activation assays. JNK
inhibitor (SP600125) prevented pramanicin-induced re-
lease of cytochrome c , caspase-9 and caspase-3 activa-
tion (Figure 6A). Caspase activation assays confirm the
inhibitory effect of JNK inhibitor. In contrast, caspase
inhibitors do not have any effect on JNK activation by
pramanicin pretreatment (results not shown).
Following characterization of JNK-caspase pathway
crosstalk, we pretreated the cells with p38 inhibitor
(SB203580) for 1 h before pramanicin (100 µM) treat-
ment and we evaluated cytochrome c release and activa-
tion of caspases. As shown in Figure 6B, inhibition of
the p38 abrogates the release of cytochrome c , as well as
the activation of caspase-9 and caspase-3 in response to
pramanicin treatment. Caspase activation assays also con-
firmed that the inhibition of the p38 pathway counter-
acted the pramanicin-induced caspase activation. Again,
caspase inhibitors showed no effect on p38 activation by
pramanicin (results not shown). The results presented in
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Figure 6. Effects of MAP kinase inhibitors on pramanicin-induced cytochrome c release and caspase activation in Jurkat cells. Jurkat
cells were pretreated with or without A, 10 µM JNK inhibitor (SP600125) B, 10 µM p38 inhibitor (SB203580) C, 10 µM ERK inhibitor
(PD98059) for 1 h and then treated with 100 µM pramanicin for 8 h. Cells were either fractioned into cytosolic or mitochondrial extracts
to detect cytochrome c release or total proteins were isolated to follow caspase-9 and caspase-3 activation by means of immunoblot
analysis as described in Materials and Methods. β-actin was probed as a loading control for all immunoblots. Fluorometric caspase
activation assays were also conducted to confirm active caspase immunoblots. D, Jurkat cells were pretreated with or without 10 µM
ERK inhibitor (PD98059) for 1 h and then treated with 50 µM pramanicin for 8 h. Cytochrome c release and activation of caspases were
detected as described above. Results of caspase activation assays are expressed as mean± SEM from three independent experiments
performed in triplicate. (Continued on next page.)
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Figure 6. (Continued).
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Figure 5A and B indicate a pro-survival role for ERK
1/2 MAP kinase pathway. Therefore, we further inves-
tigated the effect of the ERK 1/2 pathway on caspase
activation and mitochondrial cytochrome c release and as
seen in Figure 6C, incubation of Jurkat cells with ERK
1/2 inhibitor (PD98059) for 1 h before treatment with
pramanicin (100 µM) does not have any prominent ef-
fect on cytochrome c release and caspase activation. But
PD98059 pretreatment potentiates cytochrome c release,
caspase-9 and caspase-3 activation by lower concentra-
tions of pramanicin (50 µM) (Figure 6D). The caspase in-
hibitors did not show any significant effect on ERK1/2 ac-
tivation by pramanicin pretreatment (results not shown).
In summary, these findings indicate that JNK and p38
mediate pramanicin-induced activation of the mitochon-
drial apoptotic machinery, acting upstream of mitochon-
dria. Additionally the ERK1/2 pathway also acts up-
stream of mitochondria and exerts a pro-survival role in
pramanicin-induced apoptosis signalling, but its effects
can be observed at lower concentrations of pramanicin
and the potential anti-apoptotic properties of ERK1/2
activation are masked by strong pro-apoptotic signalling
triggered by pramanicin at high concentrations.
Discussion
Novel strategies in cancer prevention, diagnosis and treat-
ment have been the subject of intense research for decades.
The recognition of apoptosis as a powerful defense mech-
anism against carcinogenesis and as a target for tumor
destruction approaches reshaped cancer research and the
apoptotic machineries that are composed of signalling net-
works with modules of protein kinases, adaptor proteins
and secondary messengers have been identified.21 After
all, many chemotherapeutic agents which are already uti-
lized in cancer treatment have been shown to target intra-
and extra-cellular signalling cascades and thereby enforce
pre-malignant or malignant cells to activate their pro-
grammed cell death machineries.22–24 Identification of
key players in apoptotic signalling enables researchers to
design small molecule approaches, peptide-based thera-
peutic regimens and novel adjuvant agents for effective
and safe cancer treatment protocols.
Pramanicin is a novel antifungal agent, which was iso-
lated from a sterile fungal fermentation of Stagonospora and
it was shown to exert a potent growth inhibitory effect on
fungal organisms with minimal inhibitory concentrations
of 20–100 µM.1Harrison et al. characterized the biosyn-
thesis of pramanicin.25 Although pramanicin has been
assumed to have potential application opportunities, re-
search on its pharmacological and molecular properties on
different experimental models have only started recently.
It has been previously shown that pramanicin causes NO-
mediated and endothelium-dependent vascular relaxation
as well as a transient peak in cytosolic Ca2+ concentration
and cell death in vascular endothelial cells.2 Therefore, we
investigated the potential apoptotic effect of pramanicin
on Jurkat T lymphoblastic leukemia cells and the sig-
nalling mechanisms involved in the process.
Our results demonstrated that pramanicin treatment
induces apoptosis in Jurkat cells in a dose- and time-
dependent manner. Pramanicin at 100 µM concentration
efficiently induced apoptosis in Jurkat cells and after char-
acterization of kinetics in pramanicin-induced apoptosis,
we then tried to identify the mechanisms involved in this
apoptotic process. The release of cytochrome c is essential
for apoptosome formation and caspase-9 activation as a
part of intrinsic apoptosis signalling. Activated caspase-9
then targets downstream effector caspases, such as caspase-
3 and the activated effector caspases target intracellular
proteins for cleavage and promote the progress of pro-
grammed cell death. Here we show that pramanicin leads
to the release of cytochrome c from mitochondria and
caspase-9 and caspase-3 activation with kinetics similar
to that for induction of apoptosis. These findings indicated
a mitochondria-dependent apoptotic signalling pathway
in pramanicin-induced apoptosis.
Protein kinases are the enzymes that catalyze the phos-
phorylation of specific target proteins in response to intra-
cellular or extracellular stimuli. MAP kinases are mem-
bers of an evolutionarily conserved protein family from
yeast to complex eukaryotic organisms.7,8 MAP kinases
regulate essential cellular functions such as proliferation,
cell cycle progression, gene expression and apoptosis and
any deregulation or over activity in the phosphorelay sys-
tem of MAP kinases may lead to human pathologies
such as cancer, neurodegenerative diseases and autoim-
mune disorders.26–28 There are three main subgroups of
MAP kinases that have been defined in mammalian sys-
tems: JNK, ERKs and p38 MAP kinases. Activation of
JNK and/or p38 protein kinases has been shown to play
a critical role in programmed cell death in response to
UV and γ -ray radiation, serum deprivation, chemother-
apeutics and pro-inflammatory cytokines; although some
research groups reported that in other instances they act
either as pro-survival signals or remain unrelated to the
apoptotic process.10,11,29−31 Furthermore some reports
suggested that active ERK1/2 signaling pathways may
inhibit Fas-mediated apoptosis in T-cells and in contrast
ERK1/2 has been suggested to exert a pro-apoptotic effect
in regulation.32,33 Therefore, it can be an oversimplifica-
tion to strictly identify these kinases pro- or anti-apoptotic
and ongoing extensive research on the functional proper-
ties of MAP kinases indicate that pro-apoptotic or anti-
apoptotic actions of these kinases depend on the cell type,
duration and amplitude of activation and the presence of
other agonists/antagonists. Our results indicate that pra-
manicin leads to activation of all three MAP kinases, but
with different time kinetics and amplitudes. Pramanicin
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(100 µM) led to an early activation of p38 and a gradual
increase of p-JNK levels which reached a maximum at
4 h; as well an early but transient ERK 1/2 activation was
also induced. An interesting finding which was derived
from dose-dependent activation patterns of MAP kinases
by pramanicin was that activation of JNK and p38 kinases
was induced maximally at 100 µM pramanicin concen-
tration, but a maximal activation of ERK 1/2 could be
reached even at 50 µM pramanicin concentration. The
involvement of activated caspases and MAP kinases in
pramanicin-induced apoptosis was evaluated using their
specific inhibitors. Caspase inhibitors successfully inhib-
ited the pramanicin-induced apoptotic response and re-
vealed the functional involvement of the caspase path-
way. Pretreatment with JNK inhibitor (SP600125), p38
inhibitor (SB203580) and caspase inhibitors effectively
prevented the apoptosis induced by 100 µM pramanicin.
To our surprise, ERK inhibitor (PD98059) pretreatment
did not have any significant effect on the apoptosis in-
duced by 100 µM pramanicin, but it potentiated the
apoptotic response of Jurkat cells to 50 µM pramanicin.
All these data indicate the functional apoptotic involve-
ment of the p38 and JNK pathways and an anti-apoptotic
role for the ERK 1/2 pathway, which was masked by the
strong apoptotic response at higher concentrations of pra-
manicin but became important at lower concentrations of
pramanicin treatment. To further establish the molecu-
lar mechanisms of this differential MAP kinase involve-
ment in pramanicin-induced apoptosis, we investigated
the release of cytochrome c and caspase-9 and caspase-3
activation by utilizing pretreatments with specific MAP
kinase inhibitors before pramanicin stimulation. As ex-
pected pretreatment with JNK inhibitor (SP600125) and
p38 inhibitor (SB203580) prevented cytochrome c release
and caspase activation by 100 µM pramanicin and ERK
inhibitor (PD98059) showed no effect. Moreover, pre-
treatment with ERK inhibitor (PD98059) leads to a more
pronounced release of cytochrome c and caspase activation
by 50 µM pramanicin, which explains the enhancement
of apoptotic response of Jurkat cells to 50 µM pramanicin
after pretreatment with ERK inhibitor (PD98059). The
caspase inhibitors did not show any effect on MAP kinase
activation patterns. These findings suggest that MAP ki-
nases act upstream of caspases and they act on mitochon-
dria to control the apoptosis in response to pramanicin
treatment, either in a provocative manner as in the case of
p38 and JNK or in an inhibitive manner as in the case of
ERK 1/2.
In conclusion, we report here on the activation of an
apoptotic signaling pathway by a novel antifungal agent;
pramanicin, which involves the activation of JNK/p38
kinase cascades, mitochondrial cytochrome c release and
caspase-9/3 activation. ERK 1/2 activation can counter-
act the apoptosis induced by pramanicin only at lower
concentrations of drug-treatment through inhibition of
cytochrome c leakage and caspase activation. Altogether
these results strongly suggest pramanicin as a potential
apoptosis-inducing pharmacological agent in Jurkat cells
and studies focusing on different cancer cell lines and/or
experimental animal models will further extend our un-
derstanding of mechanisms involved in apoptotic re-
sponse to pramanicin and will allow us to better evaluate
the anti-cancer potential of this molecule.
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